Screener
Avantor AVTR Bioscience & Medtech Products — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avantor in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Avantor’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 9:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050415
| (in millions) | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Net sales: | ||||
| Bioscience & Medtech Products | $451.8 | $475.9 | $883.2 | $902.3 |
| VWR Distribution & Services | 1,240.5 | 1,207.5 | 2,390.5 | 2,362.5 |
| Total | $1,692.3 | $1,683.4 | $3,273.7 | $3,264.8 |
| Adjusted Operating Income: | ||||
| Bioscience & Medtech Products | $117.6 | $131.4 | $220.3 | $245.9 |
| VWR Distribution & Services | 126.4 | 141.6 | 231.8 | 289.5 |
| Corporate | (18.9) | (20.8) | (36.4) | (40.4) |
Item 1. Financial statements
FAQ
- What is Avantor's bioscience & medtech products — net sales?
- Avantor (AVTR) reported bioscience & medtech products — net sales of $451.8M in Q2 2026.
- What does bioscience & medtech products — net sales mean?
- This metric represents the total revenue generated from the sale of products and services specifically within the Bioscience and Medtech business segment. It serves as a primary indicator of market demand and the company's ability to capture value within the biopharma and healthcare sectors.
Ask your AI about Avantor's bioscience & medtech products — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude